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A B S T R A C T
The best antibiotic regimen for acute prosthetic
joint infection, treated without removal of the
implant, has not been well-defined. This study
describes the use of a protocol based on oral
rifampicin combinations to treat 47 cases that
were followed prospectively for a 2-year period.
The regimen used most commonly was levofloxa-
cin 500 mg ⁄ 24 h plus rifampicin 600 mg ⁄ 24 h for
a mean duration of 2.7 ± 1 months. The cure rate
was 76.9%, and the only independent risk-factor
associated with treatment failure was infection
caused by methicillin-resistant Staphylococcus au-
reus or Enterococcus spp. (OR 17.6, p 0.003).
Overall, the results suggested that use of oral
antibiotics, including rifampicin, for 2–3 months
was a good treatment option.
Keywords Acute prosthetic joint infection, antibiotic
regimen, levofloxacin, rifampicin, treatment
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Acute post-surgical prosthetic infection can be
treated successfully by open debride´ment and
prolonged intravenous antimicrobial therapy.
However, it has not yet been established which
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antibiotic, or combination of antibiotics, is the
most appropriate choice, or for how long treat-
ment should be administered. This study presents
the results of a treatment protocol based on open
debride´ment and leaving the prosthesis in place.
In addition, independent variables associated
with treatment failure are analysed.
Acute deep post-surgical infection was consid-
ered when infection appeared within the first
3 months after arthroplasty and the patient had
inflammatory signs, increased levels of C-reactive
protein, and yielded pathogenic microorganisms
from deep samples, and ⁄ or pus was present.
Once samples were taken, treatment with a
broad-spectrum parenteral antibiotic was com-
menced, with treatment modified subsequently
according to the organism’s antibiogram, giving
priority to oral combinations containing rifampi-
cin. Oral dosages of levofloxacin, clindamycin
and rifampicin were 500 mg ⁄ 24 h, 300 mg ⁄ 8 h
and 600 mg ⁄ 24 h, respectively. The intravenous
dosage of teicoplanin was 10 mg ⁄ kg ⁄ 24 h. Anti-
biotic treatment was continued until resolution of
clinical signs and normalisation of CRP levels
(< 1 mg ⁄dL).
Patients were followed for a minimum of
24 months. Outcome was evaluated according to
the following definitions: (i) cured, when the
patient was asymptomatic, the prosthesis was
functioning well, and the CRP level was
< 1 mg ⁄mL, or when the patient developed a
non-septic complication that required prosthesis
replacement and cultures of deep tissues were
negative; (ii) failure, when inflammatory signs and
high CRP levels remained during treatment, or re-
appeared after completing treatment; and (iii)
non-evaluable, when the patient died before treat-
ment was completed.
Statistical analysis was performed using SPSS
software (SPSS Inc., Chicago, IL, USA). For univa-
riate analyses, categorical variables were com-
pared using the chi-square test or Fisher’s exact
test, and quantitative variables were compared
using the Students t-test or ANOVA. A logistic
regressionmodelwasused to identify independent
variables associated with treatment failure. Varia-
bles included in the statistical analysis were age,
co-morbidity, type of prosthesis, route of adminis-
tration and duration of antimicrobial treatment,
and the aetiological agent. Statistical significance
was defined as a two-tailed p value < 0.05.
During the study period, 47 patients were
investigated. The mean age (SD) was 76.1 (10)
years, 23 patients were male and 24 were female.
Twenty-one cases involved a hemiarthroplasty
(HA), 11 involved a total hip arthroplasty (THA),
and 15 involved a total knee arthroplasty (TKA).
The mean time from arthroplasty to the diagnosis
of infection was 25.7 (16.8) days. Eight patients
(seven HA and one THA) died within a few days
of being diagnosed and were thus non-evaluable.
The mean (SD) duration of antimicrobial treat-
ment was 2.7 (1) months, with 30 patients treated
by the oral route and nine treated intravenously.
Outcome according to the type of implant and
aetiology is summarised in Table 1. The duration
and efficacy of the three antimicrobial regimens
used most frequently are shown in Table 2. The
duration of antibiotic treatment was similar for all
microorganisms.
Table 1. Patient outcome according to aetiological agent and type of implant
Microorganism
Hemiarthroplasty (n = 21) Total hip arthroplasty (n = 11) Total knee arthroplasty (n = 15)
Evaluablea Cured (%) Evaluablea Cured (%) Evaluablea Cured (%)
Gram-positive cocci 10 8 (80) 9 8 (88.9) 12 6 (50)
Staphylococcus aureus 4 4 (100) 1 1 (100) 6 2 (33.3)
Methicillin-susceptible 3 3 (100) 1 1 (100) 3 2 (75)
Methicillin-resistant 1 1 – – 3 0
Coagulase-negative staphylococci 3 3 (100) 6 6 (100) 5 3 (60)
Methicillin-susceptible – – 3 3 2 1 (50)
Methicillin-resistant 3 3 3 3 3 2 (75)
Streptococcus viridans 1 1 (100)b 1 1 (100) 1 1 (100)
Enterococcus spp. 2 0 (0) 1 0 (0) – –
Gram-negative bacilli 3 3 (100)c – – 1 1 (100)
Culture-negative 1 1 (100) 1 1 (100) 2 2 (100)b
Total 14 12 (85.7) 10 9 (90) 15 9 (60)
aPatients who completed antimicrobial therapy.
bOne patient developed an aseptic loosening after 24 months.
cOne patient had a prosthesis luxation after 6 months and cultures were negative.
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Thirty (76.9%) of the 39 evaluable patients were
classified as cured; 27 maintained the prosthesis
in place with good mechanical results after
follow-up for 24 months, and the prosthesis was
removed because of non-septic complications in
three cases. Nine patients were classified as
treatment failure (23.1%). The only independent
factor associated with failure in the multivariate
analysis was infection caused by Enterococcus spp.
or methicillin-resistant Staphylococcus aureus
(MRSA) (OR 17.6, 95% CI 1.3–238.3, p 0.003).
Open debride´ment combined with administra-
tion of intravenous b-lactam agents for 4–6 weeks
has been reported to have a success rate of < 50%
with S. aureus infections [1–3], but a combination
of rifampicin with other antibiotics has been
demonstrated in recent years to have a higher
success rate [4–7]. The protocol used in the
present study for treatment of acute post-surgical
prosthetic infection gave priority to levofloxacin
plus rifampicin. Levofloxacin was preferred over
ciprofloxacin because of: (i) its better therapeutic
index as a consequence of a lower MIC for
S. aureus and a high serum concentration (higher
bioavailability); (ii) the advantages of once-daily
administration; and (iii) its bactericidal activity
against staphylococci in a non-growing state [8],
which probably makes it more active against
bacteria living in a biofilm, especially when
combined with rifampicin.
The results suggested that rifampicin
600 mg ⁄ 24 h was as effective as the regimen of
450 mg ⁄ 12 h used previously [7]. Rifampicin is a
concentration-dependent antibiotic, and the best
pharmacodynamic parameter related to its activ-
ity is Cmax ⁄MIC [9]. Rifampicin as a 600-mg
mono-dose is easier to administer and could also
result in a higher Cmax ⁄MIC than a dose of
450 mg ⁄ 12 h. The results in Table 2 show that the
once-daily regimen of levofloxacin plus rifampi-
cin had the highest cure rate of 92.3%.
The only independent risk-factor for failure
was infection caused by MRSA or Enterococcus
spp. (OR 17.6, 95% CI 1.3–238.3). Previous experi-
ence with high doses and prolonged courses (6–
9 months) of co-trimoxazole for infections caused
by MRSA showed a 50% and 62% success rate
with THP and TKP infections, respectively [10].
However, 20% of patients stopped treatment
because of adverse events. Other active antimi-
crobial agents with good preliminary results, such
as linezolid [11–13], should also be investigated.
Although the logistic regression model showed
that the type of implant was not a factor associ-
ated with treatment failure, the cure rate was
lower in patients with a TKA (60% vs. 90% and
85.7% for THA and PHA, respectively). This was
probably associated with the fact that MRSA was
isolated more frequently from knee prosthesis
infections than from other infections. However,
previous studies have reported a high failure rate
in the treatment of knee prosthesis infections
[3,14], indicating that this aspect deserves further
investigation.
In conclusion, the results of this study suggest
that acute post-surgical infection of joint arthro-
plasty caused by methicillin- and fluoroquino-
lone-susceptible staphylococci or streptococci can
be treated with open debride´ment and the use of
oral antimicrobial agents for a 2–3-month period.
Infections caused by MRSA or Enterococcus spp.
were associated with a high rate of treatment
failure, making it necessary to evaluate new
agents active against these pathogens.






Microorganisms (number cured/number treated)
CNS (MR) SAU (MR) STR ENT GNB CN
Lev + Rif 2.5 (1.1) 12 ⁄ 13 (92.3) 5 ⁄ 6 (1) 5 ⁄ 5 1 ⁄ 1 – – 1 ⁄ 1
Clin + Rif 3 (1.3) 72 ⁄ 10 (70) 4 ⁄ 4 (4) 1 ⁄ 3 (1) 2 ⁄ 3 – – –
Tei (alone or in combination) 2.8 (1) 5b ⁄ 8 (62.5) 2 ⁄ 2 (2) 0 ⁄ 1 (1) – 0 ⁄ 2 – 3 ⁄ 3
Other regimens 2.5 (0.7) 6c ⁄ 8 (75) 1 ⁄ 1 (1) 1 ⁄ 2 (2) – 0 ⁄ 1 4 ⁄ 4 –
Total 30 ⁄ 39 (76.9) 12(6) ⁄ 13(8) 7(1) ⁄ 11(4) 3 ⁄ 4 0 ⁄ 3 4 ⁄ 4 4 ⁄ 4
SD, standard deviation; Lev, levofloxacin; Rif, rifampicin; Clin, clindamycin; Tei, teicoplanin; CNS, coagulase-negative staphylococci; SAU, Staphylococcus aureus; MR,
methicillin-resistant; STR, Streptococcus spp.; ENT, Enterococcus spp.; GNB, Gram-negative bacilli; CN, culture-negative.
aEvaluable, patients who completed antimicrobial therapy.
bOne patient developed an aseptic loosening.
cOne patient had a prosthesis luxation after 6 months and cultures were negative.
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A B S T R A C T
This retrospective cohort study examined the
clinical significance of isolated Staphylococcus
aureus central venous catheter (CVC) tip cultures
(i.e., positive tip cultures without concomitant
positive blood cultures). Subsequent S. aureus
bacteraemia was found in nine (12%) of 77
patients at a median time of 4 days after CVC
removal. A high co-morbidity score and no
effective antibiotic treatment within 48 h of CVC
removal were independent risk-factors for septic
complications following multivariate analysis. A
matched case-control study that compared the
above cohort with patients with CVC tip cultures
negative for S. aureus supported the significance
of these findings.
Keywords Bacteraemia, central venous catheter, risk-
factors, significance, Staphylococcus aureus, tip cultures
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Few data exist concerning the clinical signifi-
cance of central venous catheter (CVC) tip
cultures that are positive for Staphylococus aureus
in patients who have no blood cultures collected
around the time of CVC removal, or whose
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